ABL Bio partners with Sanofi to develop Parkinson’s disease treatment

Clinical-stage biotech developer ABL Bio Inc. announced it will collaborate and enter a worldwide license agreement with Sanofi to develop and commercialize a treatment for Parkinson’s disease and other potential indications.

The treatment, ABL301, is a preclinical stage bispecific antibody that targets alpha-synuclein and insulin-like growth factor 1 receptor (IGF1R) with bolstered penetration of the blood-brain barrier, according to a press release from ABL.

Once the transaction becomes effective, Sanofi will have worldwide exclusive development and commercialization rights to the treatment, and ABL will lead preclinical development and the phase 1 clinical trial, according to the release. Sanofi will then handle additional clinical development, regulatory approval and commercialization worldwide.

ABL301 uses Grabody-B technology, which is a blood-brain barrier shuttling platform targeting the IGF1R.

“This groundbreaking partnership with Sanofi proves the immense possibilities of ABL's innovative bispecific antibody technology,” Sang Hoon Lee, PhD, CEO of ABL Bio, said in the release. “We will continue to develop our Grabody-B platform and expand its applicability in other neurodegenerative diseases, such as Alzheimer's, to contribute to improving the lives of patients worldwide.”